

## Model for regulation of the histidine operon of *Salmonella*

(gene regulation/antitermination control/leader peptide/alternative stem model/mRNA structure)

H. MARK JOHNSTON\*, WAYNE M. BARNES†, FORREST G. CHUMLEY\*, LIONELLO BOSSI\*‡, AND JOHN R. ROTH\*

\*Department of Biology, University of Utah, Salt Lake City, Utah 84112; and †Department of Biochemistry, Washington University Medical School, St. Louis, Missouri 63110

Communicated by Bruce N. Ames, September 4, 1979

**ABSTRACT** A model is proposed that accounts for regulation of the histidine operon by a mechanism involving alternative configurations of mRNA secondary structure (the alternative stem model). New evidence for the model includes sequence data on three regulatory mutations. The first (*hisO1242*) is a mutation that deletes sequences needed to form the attenuator mRNA stem and causes constitutive operon expression. The second mutation (*hisO9654*) is a His<sup>-</sup> ochre (UAA) mutation in the leader peptide gene; the existence of this mutation constitutes evidence that the leader peptide gene is translated. The third mutation (*hisO9663*) is remarkable. It neither generates a nonsense codon nor affects a translated sequence; yet, it is suppressible by amber suppressors. We believe this mutation causes a His<sup>-</sup> phenotype by interfering with mRNA secondary structure. The suppressibility of the mutation is probably due to disruption of the attenuator stem by ribosomes that read through the terminator codon of the leader peptide gene. This explanation is supported by the observation of derepression of a wild-type control region in the presence of an amber suppressor. Evidence is presented that *hisT* mutants (which lack pseudouridine in the anticodon arm of histidine tRNA) may cause derepression of the *his* operon by slowing protein synthesis in the leader peptide gene.

The histidine operon is a cluster of nine genes whose expression increases in response to histidine starvation. Regulation seems to be achieved without any purely regulatory protein. Here we present a model for regulation of this operon and some preliminary data that support that model.

### The background

Our current understanding of this regulatory mechanism rests on several sorts of data. A large number of constitutive mutants have been isolated. These mutants fall into six classes, one mapping near the operon (*hisO*), the others (*hisR*, *S*, *T*, *U*, and *W*) mapping at separate positions far from the operon (1, 2). None of the unlinked mutations appears to affect a repressor protein; all seem to affect the amount or the structure of histidyl-tRNA (3-9). Therefore, the mechanism regulating operon expression must sense the level of histidyl-tRNA (10, 11). Five of the six classes of "regulatory" mutations generate a derepression signal without directly affecting the regulatory region. The *hisO* mutations may be the only class that directly affects the regulatory apparatus. The *hisO* mutations are dominant and affect only genes contiguous (*cis*) to the mutant site; mutations in the other regulatory genes are recessive (refs. 12 and 13; unpublished results).

Transcription of *his* operon DNA *in vitro* revealed that the control region includes a barrier to transcription (14). This barrier, termed the attenuator site, is apparently removed or damaged by *hisO* constitutive mutations. It was suggested that

regulation is achieved by altering the frequency with which transcription crosses this attenuator site.

By use of an *in vitro* system that permits transcription of the operon either coupled with or uncoupled from translation (15), it was demonstrated that transcription through the attenuator and into the structural genes of the operon occurs only when translation is occurring simultaneously.

The DNA sequence of the histidine operon control region (*hisO*) was determined by Barnes (16). This sequence includes two particularly interesting features: (i) A sequence with dyad symmetry is present which, if transcribed into message, would permit formation of a perfect 14-base-pair stem and loop. This mRNA stem includes a region rich in G and C residues and is followed by nine U residues. Structures of this type have been associated with message-termination signals in several other systems (17-23). It seemed likely that the attenuator site (14) might encode this mRNA structure (the attenuator stem). (ii) The control region was also found to contain a sequence that could encode a peptide of 16 amino acids. The gene for this peptide includes seven adjacent histidine codons! It was suggested that the translation requirement for *in vitro* operon expression might involve this tiny gene. The run of histidine codons could provide a sensitive means for determining the concentration of histidyl-tRNA to which operon control responds.

The role of the leader peptide gene in regulation has been speculative. No direct evidence has previously linked this gene or the putative attenuator stem to operon control. Here we propose a model mechanism for regulation of the histidine operon and present preliminary data that support several aspects of this model.

### Model for regulation of histidine operon

The model assumes that formation of the 14-base-pair stem (the attenuator stem) in the histidine mRNA causes RNA polymerase to terminate transcription at the run of U residues following that stem. If formation of this stem is prevented, then RNA polymerase proceeds across the attenuator site and into the structural genes. Formation of the attenuator stem is prevented when the promoter-proximal (5') half of the stem is already involved in alternative secondary structure at the time that the distal (3') portion of the stem is synthesized. Fig. 1 presents three possible configurations that might be assumed by the leader portion of the histidine mRNA. Fig. 1 *a* and *c* presents structures that include the attenuator stem (EF) and, thus, would cause repression of operon expression. The configuration in Fig. 1 *b* does not include the attenuator stem and, thus, would permit full operon expression. Fig. 1 *c* shows three main stem-loop structures which are designated AB, CD, and EF (attenuator). These letters refer to stretches of message se-

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.

‡ On leave from I Istituto di Chimica Biologica, II Facoltà di Medicina e Chirurgia, University of Naples, Italy.




FIG. 1. Alternative secondary structures for the histidine leader mRNA. The stems presented can be drawn in several slightly different ways; in each case the form was chosen that is predicted to be thermodynamically favored. Free energy of formation of each of these stems was calculated (24, 25) and is as follows: AB,  $-16.2$  kcal; BC,  $-10.2$  kcal; CD,  $-11.2$  kcal; DE,  $-15.9$  kcal; and EF,  $-38.4$  kcal. Numbered pointers refer to base changes in mutants of *Salmonella* or differences between the *Salmonella* and *Escherichia coli* sequences. Base 1 is changed to an A in mutant *hisO9663*; base 2 is a G in *E. coli*; base 3 is a C in *E. coli*; base 4 is changed to T in mutant *hisO9654*.

quence designated in Fig. 1. The configuration in Fig. 1b is generated by an alternative pairing arrangement of these same stretches to form new stem-loop structures BC and DE. We assume that these stems, once formed, are relatively stable on the time scale involved in making the regulatory decision.

The model proposes that the configuration assumed by the message depends on whether sequences are available for pairing with newly made mRNA. For example, newly synthesized sequence C (see Fig. 1) can form a BC stem if B is not already paired; if B is involved in a preexisting AB stem, C will be unable to pair until the subsequent D sequence is made and the CD stem can form.

The model assumes that availability of mRNA sequences for pairing is affected by the position of the first ribosome on the nascent mRNA. It is presumed that ribosomes are capable of disrupting mRNA secondary structure as they translate the message. More explicitly, we assume that a ribosome disrupts 12 bases of message structure ahead (at the 3' side) of the codon occupying the aminoacyl-tRNA site on the ribosome (26). The mechanism proposed works even if the extent of mRNA structure disruption is varied slightly from this assumed value of 12. The ramifications of these assumptions are presented in Fig. 1.

The repressed operon is presented in Fig. 1a. It is assumed that when an excess of histidyl-tRNA is available, the first ribosome follows RNA polymerase closely through the leader

peptide as far as the termination codon UAG. This disrupts mRNA secondary structure involving sequences A and B. As the polymerase proceeds, leaving ribosomes behind, the CD and EF (attenuator) stems form and message synthesis is terminated.

The fully derepressed operon is presented in Fig. 1b. Due to a shortage of histidyl-tRNA, the ribosome has fallen behind the RNA polymerase such that the fifth histidine codon in the leader peptide is occupied when polymerase is synthesizing the B sequence. In this position, the ribosome prevents A sequences from pairing with B. Because the AB stem cannot form, B is available to pair with C as polymerase progresses. Thus, the BC and DE stems form and no attenuator stem is made.

Fig. 1c presents a situation in which the ribosome has failed to reach the first histidine codon. This situation would arise in the absence of aminoacyl-tRNAs for any of the earlier codons in the leader peptide or if protein synthesis were totally prevented. Under such circumstances, the AB, CD, and EF (attenuator) stems form, causing termination of transcription. This situation may account for the *in vitro* termination of transcription in the absence of protein synthesis (14, 15). It should be noted that termination is associated with formation of both the CD and EF stems. Determination of sequence alterations in a variety of mutants should help decide if both stems are essential for termination.

We realize that the above scenario and the three panels in Fig. 1 describe extremes. In fact, ribosomes probably do not "arrest" but rather are slowed so that their separation from polymerase permits or prohibits the mRNA secondary structures described. It seems reasonable to treat this as a kinetic model in which the stem loop structures may never come to thermodynamic equilibrium; however, the relative stabilities of these stems will necessarily affect operational details of the mechanism.

### New data supporting the model

**Identification of Attenuator.** A constitutive mutation (*hisO1242*) prevents the termination of mRNA synthesis at the attenuator. The extent of the *hisO1242* deletion, determined by DNA sequencing, is presented in Fig. 2. It is apparent that this mutant, known to be defective in attenuation, lacks the ability to form the EF stem. This result suggests strongly that this mRNA stem is essential for transcription termination.

**Genetic Map of *hisO* Region.** A detailed fine-structure genetic map of the control region has been constructed (Fig. 3); the map is an extension and revision of an earlier map (27). The new map is based on over 30 deletions having at least 15 distinct endpoints within this region. Many new regulatory mutants have been placed on this map.

Auxotrophic ( $\text{His}^-$ ) nonsense mutations are among the new mutations in the control region. The existence of nonsense mutations argues strongly that some portion of the control region is translated. This translated region is clearly located between the promoter and the attenuator site (*hisO1242*). Many of the  $\text{His}^-$  mutations mapping in this region revert to  $\text{His}^+$  with high frequency; this instability is predicted by the model and will be discussed below.

**The Leader Peptide Gene Is Translated.** Proof that the leader peptide gene is in fact translated is provided by the existence of a nonsense mutation in this gene. Mutation *hisO9654* is one of the regulatory mutations mapping promoter-proximal to the attenuator. This mutation causes a  $\text{His}^-$  phenotype, and is suppressed by several ochre suppressors. The DNA sequence alteration caused by this mutation creates an ochre (UAA) codon in the *his* leader peptide gene (Fig. 2). Our model predicts that termination of protein synthesis preceding the run




FIG. 2. Mutations affecting the *hisO* region sequence. Wild-type sequence (as mRNA) is presented. Sequences not listed are replaced by horizontal bars (—). Letters below the sequence refer to portions of the sequence as described in Fig. 1. The size of the region encoding the normal leader peptide is indicated; also indicated is the region thought to be translated in the presence of an amber suppressor to yield a larger readthrough peptide.

of histidine codons would cause formation of the attenuator stem, (Fig. 1c) and lead to transcription termination. The fact that the ochre mutation is His<sup>-</sup> supports our model. Suppression of this mutation despite the low efficiency of ochre suppressors is consistent with the fact that very low operon expression ( $\approx 1/10$  of basal levels) is sufficient for a His<sup>+</sup> phenotype.

**A Novel Suppressible Regulatory Mutation.** A problem arose in accounting for some of the other suppressible His<sup>-</sup> mutations. The sequence of the leader peptide gene includes no codons that can be converted to UAG or to UGA by a single base substitution. Yet eight amber-suppressible mutations and one UGA-suppressible mutation have been found promoter-proximal to the attenuator. Mutation *hisO9663* is one of these “amber” mutations; it causes the mRNA change seen in Fig. 2. It is apparent that this “amber” mutation neither generates a nonsense codon nor is it even located in a region thought to be translated, yet it causes a His<sup>-</sup> phenotype and is corrected by amber suppressors.

The behavior of this unusual mutation is understandable in terms of the alternative stem model presented above. The position of the base substitution is marked with an arrow (base 1) in Fig. 1. The base change alters the B sequence (Fig. 1b) and seriously destabilizes the BC stem ( $\Delta G = -10.2$  kcal reduced to  $\Delta G = -3.8$  kcal). We suggest that this destabilization prevents sufficient BC stem formation and causes CD and EF (Fig. 1a) to form under all circumstances; this blocks operon ex-

pression and leads to a His<sup>-</sup> phenotype. The suppressibility of this mutation is explained in Fig. 2. Suppression of the termination codon (UAG) of the leader peptide would allow the first ribosome to read out of the peptide gene to a UGA codon at the base of the attenuator stem (see Fig. 2). A ribosome that follows the polymerase closely up to this point should disrupt the attenuator stem and thus permit polymerase to read into the structural genes. Since very little expression of the *his* operon ( $\approx 1/10$  of fully repressed levels) is needed for a His<sup>+</sup> phenotype, relatively few ribosomes would need to progress to this point. Thus, we think that mutation *hisO9663* owes its histidine requirement to excessive attenuator function. This interpretation is supported by the fact that *hisO9663* is suppressed by the attenuator deletion *hisO1242*. It seems likely that the suppressibility of *hisO9663* by amber suppressors is due to extension of the leader peptide. If this is true, these amber suppressors might affect expression of a wild-type operon.

**Operon Derepression by Amber Suppressors.** To test the effect of leader peptide extension on operon expression, we used an F' plasmid carrying a wild-type *his* control region fused to the *lac* operon of *E. coli* (unpublished data). The  $\beta$ -galactosidase gene on this plasmid is expressed and regulated by the *his* promoter and control mechanism. This plasmid was transferred to a series of isogenic *Salmonella* strains carrying various nonsense suppressors;  $\beta$ -galactosidase levels were then assayed. Results are presented in Table 1.

Most of the suppressors tested caused an increase in operon expression. Observation of this effect depends on growing cells in rich medium. Although the influence of growth conditions is not yet understood, we propose that rich medium is needed if the ribosome is to keep pace with RNA polymerase while traversing the region of stems. If it falls behind (perhaps due to slight shortages of any of a variety of charged tRNAs), the attenuator stem can again form and cause repression.

**Comparison of *E. coli* and *Salmonella* Leader Sequences.** The DNA sequence of the *his* control region has been determined for *E. coli* (32) and *Salmonella* (16). Only two differences are seen among the 151 base pairs from the leader peptide AUG codon through the 3' base of the attenuator stem. This high degree of sequence homology contrasts with the general extent of sequence divergence between the two species, which has been estimated as 15% (33). The close homology suggests that almost every point of the sequence has been under selective pressure. The only two differences between the *E. coli* and *Salmonella* sequences in this region (bases 2 and 3 in Fig. 1) affect residues that are not base paired in either mRNA ar-




FIG. 3. Simplified genetic map of *hisO* region. This genetic map is based on transductional crosses between over 50 point mutants and 30 deletion mutants. Only a few mutations are presented. Brackets above the genetic map enclose a description of the sort of mutations mapped in this portion of the region.

Table 1. Effect of nonsense suppressors on expression of *his* operon

Suppressor genotype	<i>his</i> operon derepression level
<i>sup</i> <sup>wt</sup>	1.0
<i>sup</i> <sup>D</sup> <sub>am</sub> (Ser)	1.2
<i>sup</i> <sup>E</sup> <sub>am</sub> (Gln)	1.3
<i>sup</i> <sup>F</sup> <sub>am</sub> (Tyr)	3.1
<i>sup</i> <sup>J</sup> <sub>am</sub> (Leu)	3.1
<i>sup</i> <sup>G</sup> <sub>oc</sub> (Lys)	2.2
<i>sup</i> <sup>C</sup> <sub>oc</sub> (Tyr)	1.1

Isogenic strains containing an F' plasmid on which the *his* operon control elements are fused to the *lac* genes of *E. coli* were assayed for  $\beta$ -galactosidase enzyme activity. The results presented are the average for two independent experiments. The  $\beta$ -galactosidase activity of the *sup*<sup>wt</sup> strain averaged 10 units, and this was defined as a derepression level of 1.0. Cells growing exponentially in an amino acid-rich medium were assayed according to Miller (28). The suppressors used were characterized by Winston *et al.* (29). The broth in which the cells were grown contained Difco Bactotryptone (10 g/liter) and NaCl (8 g/liter), with the following amino acids added (per liter): histidine (16 mg), serine (420 mg), glutamine (730 mg), tyrosine (18 mg), tryptophan (21 mg), phenylalanine (50 mg), and cysteine (36 mg). The full genotype of the strains, omitting the *sup* genotype indicated, is *his-1300 leu-414 zex-636::Tn5/F'600-1 lacI475::Tn10 hisO<sup>+</sup>G<sup>+</sup>D<sup>+</sup> (hisC-lacZ) lacY<sup>+</sup>A<sup>+</sup>*. The nomenclature for these Tn10 and Tn5 insertions has been described (30, 31).

rangement. Thus, these differences affect sites that would not affect the operation of the model as proposed above.

**A *his* Regulatory Mutation that Affects tRNA Function.** One of the regulatory mutations unlinked to the *his* operon, *hisT*, affects an enzyme that catalyzes the formation of pseudouridine ( $\Psi$ ) in the anticodon arm of many tRNA species including tRNA<sup>His</sup> (5). At first, it seemed unlikely that lack of  $\Psi$  caused a serious loss of tRNA function in protein synthesis; *hisT* mutants are viable and grow with only slightly increased generation times. Furthermore, direct *in vitro* tests of tRNA<sup>His</sup> lacking  $\Psi$  in the anticodon loop indicated that this tRNA is aminoacylated normally (34). If *hisT* mutants form tRNAs that function normally in protein synthesis, it was not clear how the *hisT* mutation could cause derepression in terms of the model presented above.

We have carried out an *in vivo* study of the effect of *hisT* on nonsense suppressors. We assume that *in vivo* suppression efficiency can be used as an indirect measure of suppressor tRNA translation efficiency. Suppression efficiency has been measured in strains with and without a *hisT* mutation. The results show that *hisT* does indeed impair the function of several tRNAs in protein synthesis. Data for the glutamine-inserting amber suppressor, *supE* (*su2*), is shown in Table 2.

We extrapolate from these observations on *supE* to an explanation of the effect of *hisT* mutations on the translation of

Table 2. Effect of *hisT* mutations on tRNA function

Relevant genotype	$\beta$ -Galactosidase, units/OD <sub>650</sub> cells	Suppressor efficiency
<i>lac</i> <sup>+</sup>	2467	—
<i>lac</i> <sup>+</sup> , <i>hisT1504</i>	2086	—
<i>lacU281</i> <sub>am</sub>	1	—
<i>lacU281</i> <sub>am</sub> , <i>supE</i>	571	23
<i>lacU281</i> <sub>am</sub> , <i>supE</i> , <i>hisT1504</i>	25	1

All strains are *Salmonella typhimurium* LT2 carrying the indicated chromosomal mutations and harboring an F'<sub>128</sub> *lac* episome. Enzyme levels were measured as described by Miller (28). The *supE* (*su2*) mutation was characterized in *Salmonella* by Winston *et al.* (29).

the *his* leader peptide. This extrapolation is attractive because tRNA<sup>His</sup><sub>CAC/U</sub> (9) and *supE* suppressor tRNA<sup>Gln</sup><sub>UAC</sub> (35) have 13-base sequences in the anticodon arm that are identical, except for differences in the anticodon itself. Both tRNAs have two adjacent  $\Psi$  residues in the anticodon loop near the base of the anticodon stem that are made by the *hisT* enzyme (5, 36). It seems possible that the efficiency of tRNA<sup>His</sup> and tRNA<sup>Gln</sup> might be impaired similarly by *hisT* mutations. We postulate that derepression of the operon caused by *hisT* mutations can be explained by impairment of translation of the *his* leader peptide (Fig. 1*b*).

## Discussion

A model has been described proposing that alternative mRNA configurations are involved in regulation of the *his* operon. This alternative stem model is similar in principle to one proposed for the *trp* operon by Lee and Yanofsky (37). An important aspect of the model presented here is the assumption that a particular stem can prevent formation of a later alternative stem even if the second stem is energetically favored. This is possible if the time involved to shift from the first stem to the second is so great that RNA polymerase would pass the critical point for termination before the attenuator stem could form.

The model proposes that message termination, and therefore regulation of the *his* operon, is mediated through translation of the leader peptide gene. This was also suggested by Barnes (16). Suppressibility of an ochre mutation in this small gene demonstrates that the leader peptide gene is in fact translated. This explains the requirement of translation for *in vitro* operon expression (15) and strengthens our belief that the ribosome is the major positive factor regulating *his* operon expression. No purely regulatory proteins are involved in the model as presented above, but it remains possible that some protein or proteins serve to stabilize loop structures of many operons. It is unlikely that the *hisG* gene product modulates regulation in any direct way (38).

The control region includes His<sup>-</sup> mutations that are unstable and revert frequently to His<sup>+</sup>. We believe that all these mutations will, like *hisO9663* and *hisO9654*, prove to affect the formation of mRNA stems or translation of the leader peptide. Their instability may be due to the large number of ways of correcting such lesions. Any secondary mutation that affects formation or stability of the attenuator stem would be expected to suppress these His<sup>-</sup> regulatory mutations. At the far left of the map is a group of stable His<sup>-</sup> mutations. These, we believe, will prove to remove or damage the *his* promoter.

Under maximally repressed conditions, the *his* operon is still expressed at a basal level. The details of how this basal level is maintained are not yet clear. The basal level does not merely reflect the extent to which the attenuator is unable to prevent readthrough. The *hisO9663* and *hisO9654* mutations owe their His<sup>-</sup> phenotype to attenuator function. Therefore, the attenuator stem appears capable of blocking virtually all transcription. We believe that the basal level will be explained by statistical fluctuations in ribosome position under repressing conditions. If, occasionally, the first ribosome is late in initiating leader peptide synthesis or is slowed by fluctuations in concentration of any of the charged tRNAs, the attenuator stem would not form. The basal level, we expect, will reflect the frequency with which such events occur under repressing conditions.

**Note Added in Proof:** An alternative stem model similar to that described here has recently been devised for regulation of the *trp* operon of *Escherichia coli* (39).

This work was supported by National Institutes of Health Grants GM23408 (to J.R.) and GM24956 (to W.B.). W.B. is the recipient of American Cancer Society Junior Faculty Research Award No. 1.

1. Roth, J., Antón, D. & Hartman, P. E. (1965) *J. Mol. Biol.* **22**, 305–323.
2. Antón, D. (1968) *J. Mol. Biol.* **33**, 533–546.
3. Roth, J. & Ames, B. (1966) *J. Mol. Biol.* **22**, 325–334.
4. DeLorenzo, F., Straus, D. & Ames, B. N. (1972) *J. Biol. Chem.* **247**, 2302–2307.
5. Singer, C., Smith, G., Cortese, R. & Ames, B. (1972) *Nature (London) New Biol.* **238**, 72–74.
6. Ciampi, M. S., Arena, F., Cortese, R. & Daniel, V. (1977) *FEBS Lett.* **77**, 75–82.
7. Bossi, L. & Cortese, R. (1977) *Nucleic Acids Res.* **4**, 1945–1956.
8. Bossi, L., Ciampi, M. S. & Cortese, R. (1978) *J. Bacteriol.* **134**, 612–620.
9. Singer, C. & Smith, G. (1972) *J. Biol. Chem.* **247**, 2989–3000.
10. Lewis, J. & Ames, B. N. (1972) *J. Mol. Biol.* **66**, 131–142.
11. Silbert, D., Fink, G. & Ames, B. (1966) *J. Mol. Biol.* **22**, 335–347.
12. Fink, G. & Roth, J. R. (1968) *J. Mol. Biol.* **33**, 547–557.
13. Ely, B. (1974) *Genetics* **78**, 593–606.
14. Kasai, T. (1974) *Nature (London)* **249**, 523–527.
15. Artz, S. & Broach, J. (1975) *Proc. Natl. Acad. Sci. USA* **72**, 3453–3457.
16. Barnes, W. (1978) *Proc. Natl. Acad. Sci. USA* **75**, 4281–4285.
17. Wu, A. & Pratt, T. (1978) *Proc. Natl. Acad. Sci. USA* **75**, 5442–5446.
18. Stauffer, G., Zurawski, G. & Yanofsky, C. (1978) *Proc. Natl. Acad. Sci. USA* **75**, 4833–4837.
19. Gardiner, J. (1979) *Proc. Natl. Acad. Sci. USA* **76**, 1706–1710.
20. Gemmill, R., Wessler, S., Keller, E. & Calvo, J. (1979) *Proc. Natl. Acad. Sci. USA* **76**, 4941–4945.
21. Zurawski, G., Brown, K., Killingly, D. & Yanofsky, C. (1978) *Proc. Natl. Acad. Sci. USA* **75**, 4271–4275.
22. Rosenberg, M., Court, D., Shimatake, H. & Brady, C. (1978) *Nature (London)* **272**, 414–423.
23. Gilbert, W. (1976) in *RNA Polymerase*, eds. Losick, R. & Chamberlin, M. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), pp. 193–206.
24. Bloomfield, V., Crothers, D. & Tinoco, I., Jr. (1974) in *Physical Chemistry of Nucleic Acids* (Harper & Row, New York), pp. 343–353.
25. Borer, P., Dengler, B., Tinoco, I., Jr. & Uhlenbeck, O. (1974) *J. Mol. Biol.* **86**, 843–853.
26. Steitz, J. (1979) in *Biological Regulation and Development*, ed. Goldberger, R. F. (Plenum, New York), Vol. 1, pp. 349–399.
27. Ely, B., Fankhauser, D. & Hartman, P. (1974) *Genetics* **78**, 607–631.
28. Miller, J. (1972) *Experiments in Molecular Genetics* (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), pp. 352–355.
29. Winston, F., Botstein, D. & Miller, J. (1979) *J. Bacteriol.* **137**, 433–439.
30. Kleckner, N., Roth, J. & Botstein, D. (1977) *J. Mol. Biol.* **116**, 125–159.
31. Chumley, F. G., Menzel, R. & Roth, J. (1979) *Genetics* **91**, 639–655.
32. DiNocera, P., Blasi, F., DiLauro, R., Frunzio, R. & Bruni, C. (1978) *Proc. Natl. Acad. Sci. USA* **75**, 4276–4280.
33. Brenner, D. J. & Falkow, S. (1971) *Adv. Genet.* **16**, 81–118.
34. Brenner, M., Lewis, J., Straus, J., DeLorenzo, F. & Ames, B. (1972) *J. Biol. Chem.* **247**, 4333–4339.
35. Yaniv, M. & Folk, W. (1975) *J. Biol. Chem.* **250**, 3243–3253.
36. Turnbough, C., Neill, R., Landsberg, R. & Ames, B. (1979) *J. Biol. Chem.* **254**, 5111–5119.
37. Lee, F. & Yanofsky, C. (1977) *Proc. Natl. Acad. Sci. USA* **74**, 4365–4369.
38. Scott, J., Roth, J. & Artz, S. (1975) *Proc. Natl. Acad. Sci. USA* **72**, 5021–5025.
39. Oxender, D. L., Zurawski, G. & Yanofsky, C. (1979) *Proc. Natl. Acad. Sci. USA* **76**, 5524–5528.